Stryker Co. (NYSE:SYK) Shares Sold by First Western Trust Bank

First Western Trust Bank lowered its position in shares of Stryker Co. (NYSE:SYK) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,497,138 shares of the medical technology company’s stock after selling 2,595 shares during the period. Stryker comprises about 56.8% of First Western Trust Bank’s holdings, making the stock its largest position. First Western Trust Bank’s holdings in Stryker were worth $1,263,376,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Hillsdale Investment Management Inc. acquired a new stake in shares of Stryker during the first quarter worth about $184,000. Trustmark National Bank Trust Department acquired a new position in shares of Stryker in the first quarter valued at approximately $283,000. O Shaughnessy Asset Management LLC raised its stake in shares of Stryker by 11.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 35,737 shares of the medical technology company’s stock worth $12,789,000 after purchasing an additional 3,800 shares during the last quarter. UniSuper Management Pty Ltd grew its position in Stryker by 169.7% in the 1st quarter. UniSuper Management Pty Ltd now owns 7,364 shares of the medical technology company’s stock valued at $2,635,000 after buying an additional 4,634 shares during the last quarter. Finally, Hilltop Partners LLC acquired a new position in Stryker in the 1st quarter valued at $236,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Up 1.8 %

Shares of SYK stock opened at $390.08 on Monday. The company has a market capitalization of $148.71 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 2.94 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $364.07 and a 200 day moving average price of $347.54. Stryker Co. has a twelve month low of $282.35 and a twelve month high of $392.70.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 earnings per share. Research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SYK. BTIG Research increased their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Royal Bank of Canada lifted their price target on Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group increased their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Needham & Company LLC boosted their target price on shares of Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company upped their price target on shares of Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $393.65.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 in the last 90 days. 5.50% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.